IP Library › Granted Patent US 12,708,614
Granted Patent B2
US 12,708,614 · App. 18/587,694 · Granted Aug 18, 2026

Ready-to-use ascorbic acid compound compositions

Inventors: Aman Trehan (Hillsborough, NJ); Ilango Subramanian (Warren, NJ); Rahul Kalhapure (Somerset, NJ); Veerappan Subramanian (Warren, NJ)
Assignee: Somerset Therapeutics LLC
A61K31/375A61K9/0019A61K9/08A61K47/02A61K47/183
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,708,614
App. No.
18/587,694
Filed
Feb 26, 2024
Granted
Aug 18, 2026
Kind
B2
Art Unit
1623
USPC
514/474
Abstract

The invention described here provides ready-to-use (RTU) pharmaceutical compositions in single unit dose packaging, such compositions including ascorbic acid compound(s), such as sodium ascorbate, and one or more pharmaceutically acceptable excipients (e.g., a carrier and optionally other agents, such as a tonicity agent, a chelator, or both). The compositions provided by the invention are stable when stored at 20° C. to 25° C.±2° C. for at least about 3 months. Compositions provided by the invention comprise an osmolality of between about 270 mOsm/kg to about 340 mOsm/kg and do not require dilution or further manipulation prior to use. In certain aspects, the invention comprises methods of using such compositions in the treatment of diseases, conditions, or symptoms related to vitamin C deficiency, such as, in specific embodiments, scurvy.

Claims (35)

1 . A ready-to-use pharmaceutical composition comprising:

(a) a unit dose amount of an ascorbic acid component comprising one or more ascorbic acid compounds, wherein the ascorbic acid component is present in the composition in a concentration of about 20 mg/mL-about 30 mg/mL; and

(b) an excipient component comprising:

(i) sodium bicarbonate in a concentration of about 10 mg/mL-about 15 mg/mL; and

ii) an ethylenediaminetetraacetic acid (EDTA) compound in a concentration that is effective to detectably enhance the stability of the composition, wherein the concentration of the EDTA compound in the composition is less than about 0.5 mg/mL, and

wherein the ready-to-use pharmaceutical composition is stable according to United States Food and Drug Administration stability standards when stored at 20° C. to 25° C.±2° C. for at least 3 months prior to use; the composition does not contain sodium diethyldithiocarbamate, and wherein the composition is adapted for parenteral administration.

2 . The ready-to-use composition of claim 1 , wherein the EDTA compound is present in the composition in a concentration of about 0.01 mg/mL-about 0.5 mg/mL.

3 . The ready-to-use composition of claim 2 , wherein the EDTA compound is present in the composition in a concentration representing less than about 0.02 mg/mL.

4 . The ready-to-use pharmaceutical composition of claim 1 , wherein the excipient component of the composition does not comprise an excipient antioxidant component comprising a compound exhibiting an antioxidant effect.

5 . The ready-to-use composition of claim 4 , wherein the EDTA compound is present in the composition in a concentration of less than about 0.02 mg/mL.

6 . The ready-to-use composition of claim 1 , wherein the EDTA compound is present in the composition in a concentration equal to or greater than 0.06 mg/mL.

7 . The ready-to-use composition of claim 1 , wherein the one or more ascorbic acid compounds are present in the composition in a concentration of about 25 mg/mL.

8 . The ready-to-use composition of claim 2 , wherein the one or more ascorbic acid compounds are present in the composition in a concentration of about 25 mg/mL.

9 . The ready-to-use composition of claim 1 , wherein the excipient component of the composition further comprises an excipient antioxidant component, wherein the excipient antioxidant component consists of one antioxidant compound exhibiting an antioxidant effect.

10 . The ready-to-use composition of claim 8 , wherein the excipient component of the composition further comprises an excipient antioxidant component, wherein the excipient antioxidant component consists of one antioxidant compound exhibiting an antioxidant effect.

11 . The ready-to-use composition of claim 1 , wherein the excipient component of the composition further comprises an excipient antioxidant component, wherein the excipient antioxidant component consists of one antioxidant compound exhibiting an antioxidant effect, and wherein the antioxidant compound of the excipient antioxidant component exhibiting the antioxidant effect is present in an amount such that the weight ratio of the antioxidant compound exhibiting the antioxidant effect to any other compound present in the composition exhibiting an antioxidant effect is not 1:1.

12 . The ready-to-use composition of claim 8 , wherein the excipient component of the composition further comprises an excipient antioxidant component, wherein the excipient antioxidant component consists of one antioxidant compound exhibiting an antioxidant effect, and wherein the antioxidant compound of the excipient antioxidant component exhibiting the antioxidant effect is present in an amount such that the weight ratio of the antioxidant compound exhibiting the antioxidant effect to any other compound present in the composition exhibiting an antioxidant effect is not 1:1.

13 . The ready-to-use composition of claim 9 , wherein the antioxidant compound of the excipient antioxidant component demonstrating the antioxidant effect is not sodium bisulfite, sodium formaldehyde sulfoxylate, or thiourea.

14 . The ready-to-use composition of claim 13 , wherein the antioxidant compound of the excipient antioxidant component demonstrating the antioxidant effect is sodium metabisulfite.

15 . The ready-to-use composition of claim 14 , wherein the sodium metabisulfite is present in the composition in a concentration of about 0.5 mg/mL to about 2 mg/mL.

16 . The ready-to-use composition of claim 10 , wherein the antioxidant compound of the excipient antioxidant component demonstrating the antioxidant effect is not sodium bisulfite, sodium formaldehyde sulfoxylate, or thiourea.

17 . The ready-to-use composition of claim 16 , wherein the antioxidant compound of the excipient antioxidant component demonstrating the antioxidant effect is sodium metabisulfite.

18 . The ready-to-use composition of claim 17 , wherein the sodium metabisulfite is present in the composition in a concentration of about 0.5 mg/mL to about 2 mg/mL.

19 . The ready-to-use composition of claim 11 , wherein the antioxidant compound of the excipient antioxidant component demonstrating the antioxidant effect is not sodium bisulfite, sodium formaldehyde sulfoxylate, or thiourea.

20 . The ready-to-use composition of claim 19 , wherein the antioxidant compound of the excipient antioxidant component demonstrating the antioxidant effect is sodium metabisulfite.

21 . The ready-to-use composition of claim 20 , wherein the sodium metabisulfite is present in the composition in a concentration of about 0.5 mg/mL to about 2 mg/mL.

22 . The ready-to-use composition of claim 12 , wherein the antioxidant compound of the excipient antioxidant component demonstrating the antioxidant effect is not sodium bisulfite, sodium formaldehyde sulfoxylate, or thiourea.

23 . The ready-to-use composition of claim 22 , wherein the antioxidant compound of the excipient antioxidant component demonstrating the antioxidant effect is sodium metabisulfite.

24 . The ready-to-use composition of claim 23 , wherein the sodium metabisulfite is present in the composition in a concentration of about 0.5 mg/mL to about 2 mg/mL.

25 . The ready-to-use composition of claim 1 , wherein the composition further comprises a pH adjustment component comprising sodium hydroxide.

26 . The ready-to-use composition of claim 25 , wherein the pH adjustment component further comprises hydrochloric acid.

27 . The ready-to-use composition of claim 1 , wherein (1) the composition has been demonstrated to be effective in treating scurvy in a statistically significant population of scurvy patients when administered in an effective daily dose for a sufficient period of time; (2) the composition is bioequivalent to a second pharmaceutical composition, wherein the second pharmaceutical composition when administered to a population of scurvy patients results in a statistically significant number of the scurvy patients being effectively treated in one or more well-controlled and adequate studies; or (3), the composition has been demonstrated to be effective in treating scurvy in a statistically significant population of scurvy patients when administered in an effective daily dose for a sufficient period of time and the composition is bioequivalent to a second pharmaceutical composition, wherein the second pharmaceutical composition when administered to a population of scurvy patients results in a statistically significant number of the scurvy patients being effectively treated in one or more well-controlled and adequate studies.

28 . The ready-to-use composition of claim 3 , wherein (1) the composition has been demonstrated to be effective in treating scurvy in a statistically significant population of scurvy patients when administered in an effective daily dose for a sufficient period of time; (2) the composition is bioequivalent to a second pharmaceutical composition, wherein the second pharmaceutical composition when administered to a population of scurvy patients results in a statistically significant number of the scurvy patients being effectively treated in one or more well-controlled and adequate studies; or (3), the composition has been demonstrated to be effective in treating scurvy in a statistically significant population of scurvy patients when administered in an effective daily dose for a sufficient period of time and the composition is bioequivalent to a second pharmaceutical composition, wherein the second pharmaceutical composition when administered to a population of scurvy patients results in a statistically significant number of the scurvy patients being effectively treated in one or more well-controlled and adequate studies.

29 . The ready-to-use composition of claim 4 , wherein (1) the composition has been demonstrated to be effective in treating scurvy in a statistically significant population of scurvy patients when administered in an effective daily dose for a sufficient period of time; (2) the composition is bioequivalent to a second pharmaceutical composition, wherein the second pharmaceutical composition when administered to a population of scurvy patients results in a statistically significant number of the scurvy patients being effectively treated in one or more well-controlled and adequate studies; or (3), the composition has been demonstrated to be effective in treating scurvy in a statistically significant population of scurvy patients when administered in an effective daily dose for a sufficient period of time and the composition is bioequivalent to a second pharmaceutical composition, wherein the second pharmaceutical composition when administered to a population of scurvy patients results in a statistically significant number of the scurvy patients being effectively treated in one or more well-controlled and adequate studies.

30 . A method of treating scurvy comprising administering to a patient diagnosed with scurvy an effective amount of the composition of claim 1 .

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 23, 2024
From: TREHAN, AMAN; SUBRAMANIAN, ILANGO; KALHAPURE, RAHUL; SUBRAMANIAN, VEERAPPAN
To: SOMERSET THERAPEUTICS, LLC
Reel/Frame 067528/0001 →
Continuity (3)
Continuation In Part 18064204 · Dec 9, 2022
Provisional Application 63288383 · Dec 10, 2021
Related Publication 20240197675A1 · Jun 20, 2024
References Cited (42)
US 9550744B2 · Sloan · 2017 [cited by applicant]
US 10039767B2 · Hashimoto · 2018 [cited by applicant]
US 20090232943A1 · Gamay · 2009 [cited by applicant]
US 20180312903A1 · Grölz · 2018 [cited by applicant]
US 20240197676A1 · Trehan · 2024 [cited by applicant]
CN 102247317A · 2011 [cited by applicant]
CN 102885771A · 2013 [cited by examiner]
CN 108158985A · 2018 [cited by examiner]
CN 111803516A · 2020 [cited by examiner]
EP 0202589B1 · 1990 [cited by applicant]
IN 448045 · 2023 [cited by applicant]
JP 2012140395A · 2012 [cited by applicant]
JP 2016104708A · 2016 [cited by applicant]
WO WO2000066599A1 · 2000 [cited by applicant]
WO WO2023237948A1 · 2023 [cited by applicant]
English translation of CN108158985A (Year: 2018). [cited by examiner]
English translation of CN111803516A (Year: 2020). [cited by examiner]
PubChem CID 54670067, “Ascorbic Acid”, Create Date Dec. 26, 2011 (Year: 2011). [cited by examiner]
Non Final Office Action on Dec. 20, 2023 for U.S. Appl. No. 18/064,222. [cited by applicant]
Non-Final Office Action on Feb. 14, 2023 for U.S. Appl. No. 18/064,222. [cited by applicant]
Final Office Action on Jul. 5, 2023 for U.S. Appl. No. 18/064,222. [cited by applicant]
Bayne A.C., “Five benefits of using antioxidants in pharma formulations,” Pharmaceutical Manufacturer, published Oct. 6, 2022. [cited by applicant]
CD Formulations, “Antioxidants.” (Year: 2023). Retrieved Nov. 21, 2023. https://www.formulationbio.com/products/antioxidants.html. [cited by applicant]
Chin et al. “Extended stability of ascorbic acid in 5% dextrose injection and 0.9% sodium chloride injection.” Am J Health-Syst Pharm. 2005; 62: 1073-4 (Year: 2005). [cited by applicant]
Fleming E, et al., “Co-delivery of synergistic antioxidants from food sources for the prevention of oxidative stress” Journal of Agriculture and Food Research, vol. 3, 2021, 100107. https://doi.org/10.1016/j.jafr.2021.1… [cited by applicant]
Final Office Action on Aug. 21, 2023 for U.S. Appl. No. 18/064,204. [cited by applicant]
Non-Final Office Action on Apr. 5, 2023 for U.S. Appl. No. 18/064,204. [cited by applicant]
Non-Final Office Action on Jan. 17, 2024 for U.S. Appl. No. 18/064,204. [cited by applicant]
Final Office Action on May 22, 2024 for U.S. Appl. No. 18/064,204. [cited by applicant]
McGuff Pharmaceutical, Inc. Ascor Product Label. “Highlights of Prescribing Information.” Revised Jul. 2022. Published Oct. 21, 2022. [cited by applicant]
Losada-Barreiro S, et al., “Biochemistry of Antioxidants: Mechanisms and Pharmaceutical Applications.” Biomedicines. Nov. 25, 2022; 10(12):3051. doi: 10.3390/biomedicines10123051. PMID: 36551806; PMCID: PMC9776363. [cited by applicant]
Pramanick S, et al. “Excipient Selection in Parenteral Formulation Development.” Pharma Times, vol. 45, No. 3, Mar. 10, 2023, p. 69 (Year: 2013). [cited by applicant]
Rowe R, et al., “Handbook of Pharmaceutical Excipients.” Pharmaceutical Press, ISBN 978 1 58212 135 2, 6th Edition, 2009, p. 45 (Year: 2009). [cited by applicant]
Shakeyla D, “Effectiveness of Antioxidants in Selected Model Drugs: Mitigation Strategy and Impact of Reformulation in Their Stability,” United States Food and Drug Administration CDER, Jun. 15, 2023. [cited by applicant]
Sheraz M, et al., “Stability and Stabilization of Ascorbic Acid A Review,” Household and Personal Care Today vol. 10(3) May/Jun. 2015. Published Jun. 2015. [cited by applicant]
Yuan, Jian-Ping and Chen, Feng. “Degradation of Ascorbic Acid in Aqueous Solution.” J. Agric. Food Chem. 1998, 46, 5078-5082. https://pubs.acs.org/doi/pdf/10.1021/jf9805404. Published on Web Nov. 21, 1998. [cited by applicant]
U.S. Appl. No. 18/587,694, filed Feb. 26, 2024, Ready-to-Use Ascorbic Acid Compound Compositions. [cited by applicant]
Arslantas A, et al. “Study of Polymorph Prediction For L-Ascorbic Acid.” Int. J. Mol. Sci. 2005, 6, 291-302. Published Dec. 6, 2005. https://doi.org/10.3390/16120291. [cited by applicant]
Bichara L, et al. “Hydration of species derived from ascorbic acid in aqueous solution. An experimental and theoretical study by using DFT calculations.” Journal of Molecular Liquids, vol. 181 (2013), 34-43. http://dx.d… [cited by applicant]
Caritá AC, et al. “Vitamin C: One compound, several uses. Advances for delivery, efficiency and stability.”Nanomedicine. Feb. 2020:24:102117. doi: 10.1016/j.nano.2019.102117. Epub Oct. 30, 2019. [cited by applicant]
Non-Final Office Action dated Aug. 26, 2024 U.S. Appl. No. 18/587,762. [cited by applicant]
Non-final office action issued Jan. 16, 2025 by USPTO. [cited by applicant]